Press releases | Deinove

31.01.2019

Deinove is preparing initiation of Phase II for DNV3837 in Clostridium difficile infections, with a key partner

The test design has been improved for a better assessment of DNV3837 effectiveness in treating Clostridium difficile infections, This will...

10.01.2019

The new DEINOVE website displays an updated presentation of DEINOVE’s corporate activities and identity It illustrates the disruptive...

22.11.2018

After launching Phyt-N-Resist® in 2018, Deinove is developing on its own a 2 nd innovative bio-based carotenoid for the cosmetics market...

21.11.2018

The equity line funding set up in December 2014 expired. It has enabled DEINOVE to raise €9.4 million net in a flexible, optimized manner...

24.10.2018

CALIBR is a division of the Scripps Research, a California non-profit corporation, dedicated to finding new treatments addressing unmet...

02.10.2018

Solvay Novecare will market Phytoene as a cosmetic active ingredient in North America and Asia under the name ReGeN-oPhyt® This agreement...

28.09.2018

The “PME Bougeons-nous” awards, organized by RMC, is the leading SME contest in France; DEINOVE was selected as the regional winner of the...

27.09.2018

Cash position: +€9.9m at June 30, 2018 compared to +€4.9m at December 31, 2017 thanks to the reinforcement of shareholders' equity Half-...

13.09.2018

UNIVAR will distribute the Phyt-N-Resist ® cosmetic active ingredient in the EMEA zone; UNIVAR is a world leader in the distribution of...

09.07.2018

DEINOVE won the “Most Innovative Technology” award, with PHYT-N-RESIST ® , during the nnual meeting point for IAR cluster members. is the...